



migami

A Brief Overview



Agenda

- **Introduction to Migami**
 - Mission Statement
 - Business Strategy
 - Management Team

- **Migami's Products**
 - QuSome Technology
 - Bi-Layer Film Strip Technology
 - Nasal Gel Delivery Technology
 - Anti-Inflammatory Peptide Portfolio

- **Manufacturing & Distribution Partners**

- **Contact Information**





Introduction to Migami: Mission Statement

Migami exists to maximize the benefits of pharmaceutical and cosmetic breakthroughs, striving to make the delivery of such products easier, simpler and more convenient. It is our belief at Migami that striving for lifelong personal health and consummate beauty should not be difficult or complicated.

In short, we believe that cosmetics and medicine should be simple and effective.





Introduction to Migami: Business Strategy

Migami's Strategic Goals Are To:

- Migami is a pharmaceutical and cosmeceutical company, and its goals are to (i) build a strong IP portfolio of acquired and/or exclusively licensed, drug-delivery platform technologies on a worldwide basis; (ii) compile a global, GMP-manufacturing capability; (iii) create a worldwide distribution channel via partnership with pharmaceutical companies; and (iv) develop a pipeline of products utilizing the advanced drug-delivery systems for existing or to-be-developed products.
- Focus resources on utilizing unique, groundbreaking delivery systems to develop the next generation of anti-aging and health products and harness established domestic and international distribution networks to launch innovative products worldwide, which will maximize shareholder value and general portfolio desirability.

Migami's Strengths Include:

- Proven track record to acquire technology and product rights
- Strong capability to optimize acquired technologies (e.g., via further development, reformulations, packaging, etc.)
- Ability to screen and identify high value, lab-tested technology aimed at revolutionizing drug delivery systems

Migami derives its revenue from upfront fees, milestone payments and royalties from distribution of licensing rights and licensed products and general pharmaceutical manufacturing partnerships





Introduction to Migami: Management Team

- **Bill Yuan, Chairman of the Executive Committee**
 - Over 23 years of Wall Street experience, with considerable experience in burgeoning Asian markets, Goldman Sachs and Merrill Lynch

- **John Park, CEO**
 - A veteran of finance, with key experience in founding corporations focused on Pacific-Rim markets

- **Tehan Oh, Secretary & Director**
 - Over 13 years of experience with initiating successful enterprises and implementing superior technological advances

- **James Polsen, CFO**
 - Equipped with over 25 years of wide-ranging experience in corporate finance, treasury management, strategic planning, and investment banking

- **Mark Wisniewski, Vice President of Business Development**
 - Over 15 years of experience in the healthcare industry

- **Dr. Young Suh, Director**
 - Well-respected dentist with offices in both Korea and the United States





Agenda

- **Introduction to Migami**
 - Mission Statement
 - Business Strategy
 - Management Team
- **Migami's Products**
 - QuSome Technology
 - Bi-Layer Film Strip Technology
 - Nasal Gel Delivery Technology
 - Anti-Inflammatory Peptide Portfolio
- **Manufacturing & Distribution Partners**
- **Contact Information**





Migami's Products: QuSome Technology

- **Migami has secured the licensing rights to proprietary QuSome technology that can be delivered orally, topically and transmucosally.**
 - QuSomes are spherical vesicles with a membrane composed of a Dag-Peg lipid used to deliver drugs or genetic material into a cell
 - QuSomes can be composed of naturally-derived Dap-Peg lipids with mixed lipid chains (e.g.. the cell membrane), thus delivering the QuSome contents with maximum efficiency and potency
 - Medical science has long recognized the considerable potential of QuSome molecules as a superior vehicle to deliver encapsulated drugs
 - Growth rate for transdermal drug delivery systems is expected to increase over 10% annually; worldwide market revenues are at \$3 Billion: 56% within the United States, 32% within Europe and 7% within Japan

QuSome technology succeeds Liposome technology, a multi-billion dollar business, as the next evolutionary step in cosmetics, topical creams, and medicine






Migami's Products: Bi-Layer Film Strip Technology

- Many pharmaceutical dosages are administered in the form of pills, granules, powders, and liquids. Some patients, particularly pediatric and geriatric patients, have difficulty swallowing or chewing solid dosage forms.
 - Pediatric and geriatric patients show a general unwillingness to take solid preparations due to fear of choking. Likewise, many pets have difficulty and / or strong resistance to taking similar medication
- Migami acquired proprietary patented technology that is a thin, flexible and quick-dissolving film. The film is placed on the top or the floor of the tongue. Instantly wet by saliva, the film rapidly hydrates and adheres onto the site of application. It then disintegrates and dissolves to release the active agent for local and / or systemic absorption.
 - Fast absorption, convenient dosing, no risk of choking, enhanced stability, improved patient compliance, transportability, ease of handling and administration
 - Offered in a variety of flavors and a variety of dissolution rates
- Migami and its partners are the first in the pharmaceutical industry to develop a drug using bi-layer film strip technology (Chloraseptic® Sore Throat Relief Strips)
- Migami and its partners forecast that the industry will exceed \$700 million in total sales for FY 2008, and \$100 million for the Company in FY 2008 for bi-layer production





Migami's Products: Bi-Layer Film Strip Technology (cont.)



* Auxiliary compounds assist with the final composition of the strips including: rate of dissolution, water solubility, mucous adhesion and coating



Migami's Products: Nasal Gel Delivery Technology

- **Nasal gel delivery systems introduce drugs / actives across the mucous membrane, which allows for the avoidance of the gastrointestinal tract and first pass liver metabolism and consequently allows the therapeutic to directly enter into circulation.**
 - Membranes are thin, allowing for the rapid uptake of a drug into the body
 - Direct absorption into body, rapid onset of desired results, and requires lower dosage
 - Delivery systems is relatively simple and comparatively inexpensive to produce

- **Delivery Types**
 - Nasal spray, pump or gel form
 - Critical Issues (exact dosage requirements, potential nasal degradation, etc.) can be modified to suit individual medications

- **Migami is also able to identify existing therapeutic modalities that would benefit from nasal gel delivery (i.e. migraine headache prevention technologies)**

- **Growth rate for nasal gel delivery systems is expected to increase 11% annually. Worldwide market revenues are at \$3 Billion with the United States at 55%, Europe at 30% and Japan at 10%**





Migami's Products: Nasal Gel Delivery Technology (cont.)

Migami and its partners invented, developed and launched 2 OTC products with a value of over \$120 million on an initial investment over \$5 million

Within five years after launch, the product brand was worth approximately \$100 million, with over \$43 million in 2003 net sales. Due to controlled development costs and a novel marketing strategy, the ROI exceeded 3,000%

InnoZen recently introduced OptiZen®, a new lubricating eye drop to provide instant relief from the symptoms associated with computer-strained eyes. OptiZen has already garnered distribution in over 15,000 US stores

InnoZen's experienced team has already formulated, developed, tested and manufactured several innovative over-the-counter health products that are ready for launch in the U.S. and overseas



➔ Migami's Products: Anti-Inflammatory Peptide Portfolio

High levels of inflammatory factors such as IL-1, IL-12, and tumor necrosis factor can contribute to premature skin aging conditions

- **Anti-inflammatory synthetic peptides CZEN 001 (KPV) and CZEN 002 derived from α Melanocyte Stimulating Hormone (α MSH)**
 - >20 years of anti-inflammation research
 - Completed preclinical, animal and human pruritus clinical studies with topical CZEN 001
 - Stability studies completed
 - Prototype topical formulations
- **Market Size: The overall skin care market is \$5.8 billion**
 - Projections to achieve \$7 billion by 2010
 - Anti-aging products are the leading market category, with an annual growth rate of 11.3%

Significant market opportunity for an anti-aging Cosmeceutical product with demonstrated anti-inflammation effectiveness based on the peptide technology



Agenda

- **Introduction to Migami**
 - Mission Statement
 - Business Strategy
 - Management Team

- **Migami's Products**
 - QuSome Technology
 - Bi-Layer Film Strip Technology
 - Nasal Gel Delivery Technology
 - Anti-Inflammatory Peptide Portfolio

▪ **Manufacturing & Distribution Partners**

- **Contact Information**





Manufacturing & Distribution Partners

- **Korean Tobacco & Ginseng / Yungjin Pharmaceutical Company, Ltd.**
 - In tandem with Migami, initiated construction of manufacturing facility in South Korea intended to serve Southeast Asian markets and dietary supplement markets within the United States
 - Committed to extensive distribution of Bi-Layer products within burgeoning Korean market
 - As of 2007, total assets exceeded \$13 billion

- **InnoZen, Inc.**
 - Wholly-owned subsidiary of HealthSport, Inc. and creator of bi-layer film technology
 - In tandem with Migami, oversees construction of manufacturing facility in Southern California

- **BioZone Laboratories, Inc.**
 - Partnering with Migami to manufacture anticipated cosmetic products, along with topical drugs using QuSome technology

- **SMI Manufacturing, LLC**
 - SMI's 90,000-square-foot, state-of-the-art, cGMP facilities are FDA inspected, European Union certified, USDA certified, OU Kosher and Halal certified





Agenda

- **Introduction to Migami**
 - Mission Statement
 - Business Strategy
 - Management Team

- **Migami's Products**
 - QuSome Technology
 - Bi-Layer Film Strip Technology
 - Nasal Gel Delivery Technology
 - Anti-Inflammatory Peptide Portfolio

- **Manufacturing & Distribution Partners**

- **Contact Information**





Contact Information

- **Migami Has Moved:**
 - 6320 Canoga Ave., Suite 1430
 - Woodland Hills, CA 91367
 - (818) 346-6300

- **To Visit Migami's Website:**
 - www.migami.net

- **For Any Additional Inquiries, Please Contact John Park (Chief Executive Officer at:**
 - jpark@migamim.net
 - 310-371-0428 (cell phone)

